Zacks: Brokerages Set $28.75 Price Target for Aptinyx Inc (APTX)
Shares of Aptinyx Inc (NASDAQ:APTX) have been given an average broker rating score of 1.40 (Strong Buy) from the five brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and four have given a strong buy recommendation to the company. Aptinyx’s rating score has declined by 40% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Analysts have set a 12 month consensus target price of $28.75 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also given Aptinyx an industry rank of 52 out of 256 based on the ratings given to related companies.
A number of equities research analysts have recently weighed in on APTX shares. Cantor Fitzgerald restated a “buy” rating and issued a $40.00 price target on shares of Aptinyx in a research note on Monday, December 3rd. BMO Capital Markets reduced their price target on shares of Aptinyx to $18.00 and set an “outperform” rating on the stock in a research note on Friday. JPMorgan Chase & Co. downgraded shares of Aptinyx from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $30.00 to $8.00 in a research note on Thursday. Finally, Leerink Swann reduced their price target on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday.
Aptinyx (NASDAQ:APTX) last issued its earnings results on Tuesday, November 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.58. The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $1.10 million. Research analysts forecast that Aptinyx will post -2.33 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in Aptinyx in the third quarter worth approximately $58,000. Strs Ohio purchased a new position in shares of Aptinyx in the third quarter valued at approximately $110,000. Wells Fargo & Company MN purchased a new position in shares of Aptinyx in the third quarter valued at approximately $185,000. American International Group Inc. purchased a new position in shares of Aptinyx in the third quarter valued at approximately $256,000. Finally, Rhumbline Advisers purchased a new position in shares of Aptinyx in the third quarter valued at approximately $287,000. Institutional investors own 64.76% of the company’s stock.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Story: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.